NCT07663734Not yet recruiting
Assessment of SMI (Superb Microvascular Imaging) for Characterising the Endocystic Material of Papillary Intraductal Mucinous Pancreatic Tumours (PIMPT)
Source: ClinicalTrials.gov · Last updated 23 Jun 2026
Brief summary (registry, in English)
There are many types of pancreatic cysts, and papillary intraductal mucinous pancreatic tumours (PIMPTs) are among the most common. PIMPTs carry a risk of progressing to a cancerous lesion. To assess this risk, the key examination involves performing an endoscopic ultrasound combined with an injection of a contrast agent called Sonovue. Superb Microvascular Imaging (SMI) is a new ultrasound modality that enables the analysis of PIMPTs without the need for a Sonovue injection. The Mermoz Endoscopy Centre will be equipped with an ultrasound console enabling SMI to be performed during an endoscopic ultrasound examination. This technology is now available on the new EUS Aplio i800 console (Canon-Olympus), which bears the CE mark. To date, no data have been published on the potential of SMI for analysing a PIMPT. This is why this clinical investigation is being conducted
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 17 Jun 2026
- Start date
- Jul 2026
- Primary completion date
- Jan 2028
- Lead sponsor
- GCS Ramsay Santé pour l'Enseignement et la Recherche
- Diseases
- Pancreatic cancer
- NCT number
- NCT07663734
What you commit to
- Study type: Interventional
- Planned participants: 60
- From Jul 2026 to the primary completion date, Jan 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient whose lesion meets the criteria for malignancy (tissue mass, metastases, ascites, vascular infiltration)
Other
- Patient for whom Sonovue is contraindicated
- Pregnant woman
- Vulnerable patient: an adult under guardianship, curatorship or other legal protection, or deprived of their liberty by a judicial or administrative decision
- Patient admitted to hospital without consent
Who the study is looking for
- Patient referred for an endoscopic ultrasound assessment of a PIMPT
- Patient with endocystic material of undetermined nature measuring 3 mm or more
- Patient registered with or covered by the social security scheme
- Patient who speaks French
- Patient who has signed an informed consent form
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hôpital Privé Jean Mermoz Coordinator of this site? Confirm its status | Lyon | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.